Eupraxia Pharmaceuticals (EPRX) Other Non Operating Income (2023 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Other Non Operating Income data on file, last reported at $2.2 million in Q1 2026.

• On a quarterly basis, Other Non Operating Income rose 4265.16% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was -$1.4 million, a 4905.89% decrease from a year earlier, with the FY2025 full-year figure at -$1.6 million, down 881.37% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $2.2 million, up from -$2.4 million in the prior quarter.
• Over the last five years, Other Non Operating Income for EPRX reached as high as $2.2 million in Q1 2026 and fell as low as -$2.4 million in Q4 2025.
• Historically, Other Non Operating Income has averaged -$113486.4 across 4 years, with a median of -$25965.0 in 2023.
• Across the five-year window, Other Non Operating Income tumbled 3316.09% in 2025 and soared 4265.16% in 2026, its largest moves.
• Year by year, Other Non Operating Income stood at $59281.0 in 2023, then tumbled by 219.85% to -$71047.0 in 2024, then tumbled by 3316.09% to -$2.4 million in 2025, then soared by 192.38% to $2.2 million in 2026.
• Per Business Quant data, the three most recent Other Non Operating Income figures were $2.2 million in Q1 2026, -$2.4 million in Q4 2025, and -$508633.0 in Q3 2025.